Studies have confirmed the safety and effectiveness of 177Lu-labeled PSMA ligands such as [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I & T in the treatment of prostate cancer, but their pharmacokinetic properties for PCa treatment, among others, still need to be improved [39,40]. The gene discussed is FOLH1; the disease is prostate carcinoma.